Novel targeted therapeutic agents, including tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and osimertinib, or monoclonal antibody cetuximab, have been developed to interfere with EGFR signaling, and show promise in the treatment of advanced NSCLC 6, 7, 8, 9, 10. This evidence concerns the gene EGFR and non-small cell lung carcinoma.